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Summary: Insulin was assayed directly using radioimmunoassay and immune-metric assay in 31 sera containing
anti-insulin antibodies. Anti-insulin antibodies were determined by radio-binding-assay. Insulin measurements were
compared with those of free (unbound to antibodies, polyethylene glycol precipitated) insulin measurements. Com-
pared with free insulin concentrations, radioimmunoassay and immunometric assay yielded falsely increased insulin
results. The degree of overestimation by radioimmunoassay and by immunometric assay correlated with the anti-
insulin antibody value. Anti-insulin antibodies still remain a possible pitfall in the insulin-specific immunometric
assays which are now being widely used.
Introduction
The availability of monoclonal antibodies to well-de-
fined sequences has made it possible to develop non-
competitive two-site immunometric assays with a high
specificity for the intact insulin molecule (1). Compared
with previous competitive one-site radioimmunoassays
(2) these new assays, now commercially available, have
greatly improved the specificity and sensitivity of
plasma insulin measurements (3). However, as recently
reviewed by Crowthers et al. (4), many problems are
still encountered in measuring insulin: sample collection
and storage, standards and quality control samples and
matrix effects. Insulin radioimmunoassay measurements
were also well-known to be falsified by endogenous
anti-insulin antibodies (5, 6). Anti-insulin antibodies are
produced during treatment with porcine or human insu-
lin, and anti-insulin autoantibodies are present in predia-
betes before any treatment with insulin (7). The aim of
this study was to establish whether anti-insulin antibod-
ies interfere with the now widely used insulin immuno-
metric assays and thus influence the interpretation of
insulin concentration.
Material and Methods
Methods
The presence of free anti-insulin antibodies (not complexed with
circulating insulin) was determined using the radioimmunopreci-
pitation technique in liquid phase: radio-binding-assay (Sanofi
Pasteur, Mames la Coquette, France). As recommended by in-
ternational workshops (8) this assay uses a monocomponent A 14
human insulin tracer. The positivity threshold was fixed by the
manufacturer at 5.5%. A binding percentage greater than this
positivity threshold indicates the presence of anti-insulin antibod-
ies.
Insulin concentrations were determined with a radioimmunoassay
kit from Sanofi Pasteur involving a guinea-pig polyclonal antibody.
The percentage of cross reaction with proinsulin is 40%. Insulin
concentrations were further determined with a microparticle en-
zyme immunometric assay kit (Abbott, Abbott Park, USA) which
allows insulin determination in the absence of cross-reactivity with
proinsulin and proinsulin-like molecules (9). This method is fully
automated on the IMx system (Abbott). Both methods are cal-
ibrated against the WHO 66/304 standard.
Free (unbound to anti-insulin antibodies) insulin was determined
with the radioimmunoassay kit after precipitation of endogenous
immune complexes by polyethylene glycol (10). Free insulin repre-
sents the biologically active form of insulin.
Specimens
We selected 31 sera from insulin-treated insulin-dependent diabetic
patients. These samples contained anti-insulin antibodies in propor-
tions determined by radio-binding-assay results ranging from 6.1
to 67%.
Results
Radioimmunoassay insulin values ranged from 18.3 to
295 mU/1, immunometric assay values from 5.7 to 220.5
mU/1, and free insulin concentrations from 2 to 45.5
mU/1 (fig. 1). Comparison of the paired radioimmuno-
assay or immunometric assay results with free insulin
concentrations showed a significant fall (t = 6.25, p =
1 · 10~7 and t = 5.82,/? = 2 · 10~6, respectively). Com-
pared to radioimmunoassay, immunometric results were
significantly lower (t = 3.95, p = 4 · 10~4).
A strong correlation was observed between the overesti-
mation of insulin concentration, measured by either
radioimmunoassay or immunometric assay, determined
as 100 X ([insulin] — [free insulin])/[free insulin] and
the percentage of anti-insulin antibodies measured by
radio-binding-assay (fig. 2). The correlation was similar
for radioimmunoassay (r = 0.79) and immunometric as-
say (r = 0.77). The degree of interference, as appreci-
ated by the slope of the regression line, was greater with
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Fig. 1 Comparison of insulin measured by radioimmunoassay
(RIA) and by immunometric assay (IMA) with free (polythylene
glycol precipitated) insulin concentration in 31 anti-insulin anti-
body positive sera.
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Fig. 2 Association of insulin overestimation determined as 100 X
([insulin] — [free insulin])/[free insulin] with anti-insulin antibody
percent determined by radio-binding-assay. Insulin measured by
radioimmunoassay (dark circles) and immunometric assay (open
circles).
radioimmunoassay (y = 14.2x + 120) than with immu-
nometric assay (y = 9.4x + 47).
Discussion
It was demonstrated, long ago, that anti-insulin antibod-
ies interfere with the radioimmunoassay of insulin. The
effect of endogenous anti-insulin antibodies is to
increase the total amount of labelled insulin bound to
endogenous human and exogenous guinea-pig antibod-
ies and to reduce the amount of labelled insulin bound
to exogenous guinea-pig antibodies. The results of com-
petitive one-site radioimmunoassay depend on the sepa-
ration method used. Non-specific precipitation of immu-
noglobulin complexes, with, for example, polyethylene
glycol, leads to false underestimated values due to over-
precipitation of the bound tracer. The double-antibody,
involved in the Sanofi radioimmunoassay used in this
study, or coated tube technology, used in today's radio-
immunoassays, results in overestimation, as too little of
the tracer is specifically bound.
Our results show clearly that anti-insulin antibodies can
also interfere with insulin immunometric determin-
ations. Immunometric assay recognised, at least par-
tially, insulin bound to endogenous antibodies, yielding
increased insulin values as compared with free insulin
concentrations. The degree of overestimation in an im-
munometric assay depends, at least theoretically and es-
pecially for small analyte molecules with a limited
number of antibody binding sites, such as insulin, on the
comparative avidity of autoantibodies and of the catcher
and tracer antibodies used in the assay. If the avidity of
the assay antibodies exceeds that of autoantibodies, the
measured concentration will tend towards the total (free
and antibody-bound) insulin concentration, i. e. yield an
overestimation of the biologically active (free) insulin in
the sample. But, if the assay antibodies are less avid
than autoantibodies, the measured concentration will
tend towards the free insulin concentration, as little or
no displacement of the autoantibody-insulin complex
takes place during the incubation time.
This may explain why the Abbott immunometric assay
was more sensitive to interference from anti-insulin anti-
bodies than the enzyme immunoassay (ELISA) studied
by Andersen et al. (11) who observed insulin concentra-
tions close to free insulin in sera containing insulin anti-
bodies with a bound fraction below 25%. Under the
same conditions, with the Abbott kit, the mean overesti-
mation was 165%.
In sera containing anti-insulin antibodies, when com-
pared with free insulin concentrations, insulin results by
immunometric assay are overestimated, but, when com-
pared with total insulin levels, they may be underesti-
mated (12). It is generally stated that anti-analyte anti-
bodies may yield a positive interference (overestima-
tion) when the result is compared with the free analyte
concentration (insulin assay for example) or a negative
interference (underestimation) when the result is com-
pared with the total analyte concentration (thyroglobulin
assay for example) (13). The relevant analyte concentra-
tion is, in the first case, that which corresponds to its
biologically active form (free form), and in the second
case, that which shows a residual secretion by thyroid
after thyroidectomy (total form).
Conclusion
Interference from anti-insulin antibodies, yielding
increased values, still remains a topical pitfall in insulin
immunometric assays. Care must be taken in the inter-
pretation of immunometric insulin results when anti-in-
sulin antibodies are present.
The solid phase antigen immunoassay described by
Wood et al. (14) could be an interesting approach to set-
tle the issue of an antibody interference-free assay, be-
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cause free thyroxin assays based on this methodology
have been shown to be much less sensitive to anti-thy-
roxin autoantibody interference than previous labelled
antigen immunoassays (15).
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